Phathom Pharmaceuticals Stock (NASDAQ: PHAT)

Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

IOVA

PHAT

QRTEA

VZIO

U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday.

Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens &amp; Minor And Other Big Stocks Moving Higher On Tuesday

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

General

PCVX

Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), 

&#34;Top Pick for 2024&#34;: Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares are trading higher Monday after the company announced FDA approval of its reformulated vo

What&#39;s Going On With Phathom Pharmaceuticals Stock?

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals Inc

Press Releases

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

Health Care

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Earnings

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Cormedix

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Maze Therapeutics

MBX Biosciences

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Trevi Therapeutics

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Phathom Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga